CA-GLOBALPLATFORM
24.5.2023 08:01:30 CEST | Business Wire | Press release
GlobalPlatform, a leading digital standards organization, has launched a broad-reaching initiative to drive engagement across security experts in the full automotive value chain and adjacent digital services. As a leader in delivering specifications and certifications for secure digital services — over 70 billion GlobalPlatform secure components deployed worldwide —GlobalPlatform is now addressing emerging automotive regulations such as new vehicle type approvals and the shift towards vehicles as a service. GlobalPlatform’s automotive initiative will optimize and accelerate the deployment of secure components, trusted digital architecture, security APIs, and security lifecycle management within the automotive sector. This initiative is being led by a dedicated Automotive Task Force to foster the alignment of GlobalPlatform technologies with automotive use cases. GlobalPlatform has also partnered with automotive standards organizations and formed the Cybersecurity Vehicle Forum to unite the automotive ecosystem in optimizing cybersecurity for vehicles.
“Recent automotive cybersecurity regulations and emerging trends like the move towards autonomous driving and flexible mobility solutions are requiring car manufacturers to become more agile and adaptable in the deployment of secure vehicle services. GlobalPlatform’s secure component technologies support the automotive sector’s compliance with these new regulations and requirements,” said Ana Tavares Lattibeaudiere, Executive Director, GlobalPlatform.
In addition to launching the Automotive Task Force, GlobalPlatform established a cooperative agreement with the Society of Automotive Engineers (SAE) to work on the harmonization of hardware-based secure execution environments in automotive. GlobalPlatform has also partnered with AUTOSAR to coordinate the alignment of secure component standards and specifications for automotive. Furthermore, GlobalPlatform has joined the Auto-ISAC community and has an active memorandum of understanding (MoU) with the Car Connectivity Consortium. These alliances will ensure coordination and alignment on common requirements with key automotive and cybersecurity organizations.
“GlobalPlatform is committed to working with the full automotive value chain to address current automotive security requirements while also focusing on developing interoperable, secure components to meet emerging vehicle standards,” said Gil Bernabeu, Chief Technology Officer, GlobalPlatform.
Another key aspect of GlobalPlatform’s automotive initiative is the launch of the Cybersecurity Vehicle Forum, which will strengthen engagement and cooperation between GlobalPlatform members and the wider automotive ecosystem. The Forum plays an invaluable role in identifying and prioritizing automotive industry requirements to deliver secure component services that span the lifecycle of a vehicle. With global events planned throughout the year, the Cybersecurity Vehicle Forum gives car manufacturers, component companies, automotive regulators, and others a platform to explore the current and future automotive use cases for trusted services and hardware-based secure services.
GlobalPlatform welcomes existing and new member contributions in developing the next generation of automotive security standards and invites the automotive ecosystem to participate in the Cybersecurity Vehicle Forum.
Contact automotive@globalplatform.org to learn more.
About GlobalPlatform
GlobalPlatform is a technical standards organization that enables the efficient launch and management of innovative, secure-by-design digital services and devices, which deliver end-to-end security, privacy, simplicity, and convenience to users. It achieves this by providing standardized technologies and certifications that empower technology and service providers to develop, certify, deploy, and manage digital services and devices in line with their business, security, regulatory and data protection needs. GlobalPlatform technologies are used in billions of smart cards, smartphones, wearables and other connected IoT devices.
GlobalPlatform standardized technologies and certifications are developed through effective industry-driven collaboration, led by multiple diverse member companies working in partnership with industry and regulatory bodies and other interested parties from around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005955/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom